Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20012423HPVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS20062038HPVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS20021743HPVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS20018182HPVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS20026301HPVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS20045849HPVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS20069030HPVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS44013052HTLV-1ENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS44045542HTLV-1ENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS44045703HTLV-1ENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TCGA Plot Options
Drug Information
GeneHIPK2
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009447
UniProt IDQ9H2X6
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830